newsfilter
← Latest News
GlobeNewswire·

BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, March 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced it has received Indep